| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $50,204,227 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL171120 | High Mechanical Shear Stress-Induced Neutrophil Dysfunction in Mechanically Assisted Circulation | 000 | 3 | NIH | 3/5/2026 | $637,830 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL172364 | Modulating the resolution of angiogenesis and normalization of the vasculature for therapeutic benefit | 000 | 2 | NIH | 2/13/2026 | $523,364 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL168775 | Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus | 001 | 3 | NIH | 3/19/2026 | $20,928 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL176934 | Macropinocytosis and Pulmonary Fibrosis | 000 | 2 | NIH | 2/11/2026 | $570,395 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL149926 | Next generation calcium channel modulators | 000 | 7 | NIH | 2/13/2026 | $711,828 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL149926 | Next generation calcium channel modulators | 001 | 7 | NIH | 3/30/2026 | $22,479 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL166402 | Targeting a Defined Surgical Stress-Induced Inflammatory Pathway to Improve Peri-Operative Outcomes | 001 | 4 | NIH | 3/13/2026 | $16,798 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL168775 | Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus | 000 | 3 | NIH | 2/11/2026 | $662,737 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL166402 | Targeting a Defined Surgical Stress-Induced Inflammatory Pathway to Improve Peri-Operative Outcomes | 000 | 4 | NIH | 1/30/2026 | $531,931 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL162940 | Computational Modeling of Device-Induced Platelet Activation and Receptor Shedding Relevant to Thrombosis and Bleeding in Device-Assisted Circulation | 001 | 4 | NIH | 3/24/2026 | $15,386 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL162940 | Computational Modeling of Device-Induced Platelet Activation and Receptor Shedding Relevant to Thrombosis and Bleeding in Device-Assisted Circulation | 000 | 4 | NIH | 2/6/2026 | $487,205 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD093070 | VEGF Gene Delivery In The Primate To Prevent Defective Spiral Artery Remodeling And Maternal Vascular Dysfunction | 001 | 8 | NIH | 3/27/2026 | $663,053 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD108705 | Intersection of the mTOR/p70S6K1 signaling and the HIPPO-Yap tissue organizer in neurulation and diabetic embryopathy | 001 | 4 | NIH | 3/27/2026 | $65,182 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD108705 | Intersection of the mTOR/p70S6K1 signaling and the HIPPO-Yap tissue organizer in neurulation and diabetic embryopathy | 000 | 4 | NIH | 1/23/2026 | $586,642 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD111480 | Screen and functional validation of Pediatric Cardiomyopathy genetic variants in Drosophila | 000 | 4 | NIH | 3/19/2026 | $650,351 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK133421 | Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | 000 | 4 | NIH | 12/30/2025 | $538,952 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01ES033301 | Impact of Cadmium Exposure on Transporter Function and Drug Disposition in the Kidney | 000 | 5 | NIH | 4/1/2026 | $363,710 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK130238 | Pharmacogenetics of the Response to a GLP1R Agonist | 000 | 5 | NIH | 12/4/2025 | $672,063 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK109581 | Assessment of Donor Quality for Improving Kidney Transplant Outcomes | 000 | 8 | NIH | 1/28/2026 | $618,786 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK074797 | Inter-organ signaling in heme metabolism and organismal homeostasis. | 000 | 15 | NIH | 12/30/2025 | $397,410 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK068491 | Surgical Studies of Gut Permeability | 001 | 19 | NIH | 3/26/2026 | $687,002 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA298839 | Tumor-associated pDC (TApDC) in liver cancer with HIV infection | 000 | 2 | NIH | 12/11/2025 | $570,655 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA292106 | Chemotherapy induced MASP activation and ovarian cancer metastasis | 000 | 2 | NIH | 1/13/2026 | $415,963 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DC012564 | Usher Proteins in the Inner ear Structure and Function | 001 | 14 | NIH | 2/11/2026 | $62,254 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DC012564 | Usher Proteins in the Inner ear Structure and Function | 000 | 14 | NIH | 1/21/2026 | $560,296 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA055634 | Influence of Orexin Antagonism on Methamphentamine Demand | 002 | 4 | NIH | 3/16/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA055634 | Influence of Orexin Antagonism on Methamphentamine Demand | 001 | 4 | NIH | 3/6/2026 | $593,386 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA039062 | Endocannabinoids regulate microglia in developing brain | 000 | 10 | NIH | 2/27/2026 | $469,533 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA063051 | Behavioral and neurobiological mechanisms of reciprocal social interactions in Substance Use Disorders | 000 | 2 | NIH | 3/19/2026 | $641,450 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA065079 | Impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. | 000 | 1 | NIH | 3/10/2026 | $685,937 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM156369 | Conformational Dynamics and Regulatory Mechanisms in the KCNH Family of Ion Channels | 000 | 2 | NIH | 12/24/2025 | $384,863 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37NS141786 | SGLT2 - Novel Molecular Mechanism of AQP4 Regulation | 000 | 1 | NIH | 3/5/2026 | $602,065 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37NS125632 | KPTN Loss and Megalencephaly: mTOR Activation as Therapeutic Target | 000 | 5 | NIH | 3/23/2026 | $273,597 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37MH080046 | Internal Dynamics of the Postsynaptic Density | 000 | 19 | NIH | 12/23/2025 | $679,801 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37AI062765 | Regulatory T Cells and Lymphatic Endothelial Cells: Regulatory Interactions for Migration and Suppression | 000 | 22 | NIH | 3/27/2026 | $559,800 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM144147 | Photonics-based Fluorescence Imaging for Research, Diagnostics, and Pathology | 001 | 5 | NIH | 3/23/2026 | $38,625 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM144147 | Photonics-based Fluorescence Imaging for Research, Diagnostics, and Pathology | 000 | 5 | NIH | 1/26/2026 | $347,625 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R24DA061178 | ARTEMIS: Advancing Addiction Research and Treatment through Engagement with Rural Marylanders Impacted by PolySubstance Use | 001 | 3 | NIH | 4/1/2026 | $418,762 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25DE032530 | Maryland Program in Dental Research Experience (D-REX) | 000 | 4 | NIH | 1/13/2026 | $135,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011811 | Eastern Nigeria Research Ethics Training (ENRICH) Program | 000 | 5 | NIH | 2/27/2026 | $192,247 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21CA301173 | Associations between actigraphy-derived circadian rest-activity rhythms and cancer-related fatigue: Insights from the Harvest for Health Clinical Trial | 000 | 1 | NIH | 3/18/2026 | $411,334 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21MH136412 | White Matter Plasticity in Schizophrenia | 000 | 2 | NIH | 2/11/2026 | $240,078 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI196697 | A cord-blood specific subset of human gamma-delta T cells with distinct functional features | 000 | 1 | NIH | 2/3/2026 | $455,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS117102 | Stem Cell Surface Modification to Promote Nerve Regeneration | 001 | 5 | NIH | 3/5/2026 | $42,994 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS117102 | Stem Cell Surface Modification to Promote Nerve Regeneration | 000 | 5 | NIH | 12/18/2025 | $386,953 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS120930 | Molecular basis for adenosine A3 receptor agonists in the treatment of migraine | 001 | 5 | NIH | 3/5/2026 | $47,292 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS120930 | Molecular basis for adenosine A3 receptor agonists in the treatment of migraine | 000 | 5 | NIH | 12/18/2025 | $425,628 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS122777 | Targeting mitochondrial Complex I in neonatal hypoxia-ischemia | 001 | 5 | NIH | 3/5/2026 | $51,063 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS122777 | Targeting mitochondrial Complex I in neonatal hypoxia-ischemia | 000 | 5 | NIH | 2/5/2026 | $459,576 |
|
